Edhel Tripon

Believer, multitasking motherboard and wife, liver doc, hepatitis and liver health advocate, tries to run, reluctant multi-pet owner

[Edhel Tripon @EdhelTripon]

Seeing Babymetal with the family tomorrow! We hope to be able to get these to you, #メタラジ!🤟🫶
#Babymetalfans help us get this to them!

#BABYMETALWORLDTOUR2025
#BabyMetalManila2025
#babymetalfanart

[Scott Isaacs @scottisaacsmd]

Exercise before breakfast in the fasting state is more beneficial than postprandial morning exercise for improving liver fat and A1c.
https://t.co/8zRdmdPvU9

[Edhel Tripon @EdhelTripon]

@AnandVKulkarni2 @AASLDtweets @INASL_Liver @_LTSI_ @sonalasthana @pummy92 @CLindenmeyerMD @dean_karvellas @mcconnell_md @MaiwallRakhi Great talk Anand!

[Daniel J Drucker @DanielJDrucker]

Another outcomes trial win for GLP-1 medicines now with Semaglutide and the ESSENCE trial in metabolic liver disease with reduction in both inflammation and fibrosis #MASH https://t.co/EE8jGRnU9s

[May Lim @cxteam_lim]

Nakwento ko na dati ito dito sa Twitter (X na pala)- pero ngayon ko lang nailagay sa slides.

Kung gusto talaga nating magkaroon ng madaming travel options, kailangan nating simulan sa paglalakad. Pedestrian dapat ang priority. Pedestrian tayong lahat.

https://t.co/sMsH2Sl4pg

[Ramon Bataller @rabataller]

This important study shows three lessons:
🔸Cirrhosis is frequently underdiagnosed.
🔸Alcohol is the leading cause.
🔸HCC is not adequately screened.

Early diagnosis of silent cirrhosis can save lives !

https://t.co/RENULfbDC7

[Edhel Tripon @EdhelTripon]

Shout out and appreciation to all our extraordinary Radiology friends who go above and beyond, ask questions about the history, and are willing to look again when asked ! You help us solve mysteries and save lives everyday. Can't imagine doing Liver and GI without you guys!

[Edhel Tripon @EdhelTripon]

Reposting for #TLM2024. Taco crawl

[Bloodman @Bloodman]

Excellent state of the art paper reviewing IV Iron! https://t.co/SgOesGKokV

[Salvador Benlloch @doctorbenlloch]

Screening Strategies for High-Risk MASLD in Primary Care are cost-effective.👍💰👍
Pharmaco-economic study:👉https://t.co/1qQnaRXwGc
@Echosens @semfyc @SEMERGEN_CV @redGDPS @NovoNordiskES @EASLnews

[Edhel Tripon @EdhelTripon]

@AnandVKulkarni2 @stevenbollipo @AtoosaRabiee @DrHuangDQ @JasmohanBajaj @DrArunKValsan @AASLDtweets @AASLDPresident Hope to catch u there!

[Elliot Tapper @ebtapper]

How many people visiting diabetes clinic have advanced liver fibrosis?

Lots

Laurent went to diabetes clinic and convinced 300 people to get a liver biopsy. 1 of every 3 had advanced fibrosis

These are the people at risk for liver cancer, ascites, encephalopathy #IMTLD2024

[Edhel Tripon @EdhelTripon]

Even more frustrating when you know it's impossible to get one due to access issues :(

[Catherine Meredith @873Meredith]

It's #OrganDonatiomWeek!! Please consider joining the #OrganDonorRegister. Nearly 8,000 UK children and adults waiting for life saving #transplants. It could be you! Please #ShareYourWishes with your family as they have to give consent. #LiverTwitter. #CKD #Heart #Lungs

[Edhel Tripon @EdhelTripon]

MASLD Natural History
* 3% develop major adverse liver events within 2 decades ( 3 out of 100!)
- seems small - but the MASLD burden is Ginormous!
*Estimated progression to Cirrhosis (for those who progress)
F0-F1 --> 3 decades
F2 --> 2 decades
F3 --> 6 years

[Thomas Reiberger @ReibergerThomas]

🚨#livertwitter

#SpleenStiffness Measurement #SSM
by dedicated 100Hz #VCTE #Fibroscan probe improves #PortalHypertension risk assessment

🎯 #NICER model by @mathiasjachs @MattiasMandorf1 for the @BavenoCoop
published @LancetGastroHep
📕https://t.co/eZ5GRrhLzC

[Edhel Tripon @EdhelTripon]

More options, more reason to MDT for HCC!

[Angela Lamarca @DrAngelaLamarca]

New data for #intermediate #HCC at #ESMO24 from LEAP-012 trial

👍🏻PFS/ORR benefit for LenvaPembro+TACE (vs TACE)
🤞🏻OS promising
🤝Toxicity acceptable

👉Systemic+TACE as SOC may be close to be a reality!! (2nd +ve study 😉 EMERALD-1)

@myESMO #ESMOAmbassadors @GrupoTTD @EASLnews

[Arndt Vogel @ArndtVogel]

TACE +/- lenva + pembro for intermediate-stage HCC
#ESMO24
🔎Phs III LEAP-012
👉ORR 46 vs 33% (RECIST)
👉ORR 71 vs 49% (mRECIST)
👉mPFS 10 vs 14.6 mo
👉mOS not mature
👉AE ≥3 31% vs 71%
🧐strong ORR and PFS data, already practice-changing?
@myESMO #ESMOAmbassadors

[Steven Bollipo @stevenbollipo]

Confused by BRTO, CARTO, PARTO? This slide from Ken Chan is for you!
Just say, "embolization of varices"
#livertwitter #AGW2024

[Jasmohan Bajaj @JasmohanBajaj]

Less=More w #antibiotics in #cirrhosis & ✅
reconsider #SecSBPProphylaxis
@AmJGastro⤵️
https://t.co/oW8wyJ3n3v
🔑#SecSBPPr vs others▶️⬆️SBP recurrence &🚫mortality benefit
🔑2 datasets (@VAResearch & @TriNetX) w similar trends
🔑worsens over time & validated locally
@ABsteward

[Michael Weintraub, MD @MWeintraubMD]

Tirzepatide was associated with 48% decreased kidney events compared to GLP1 RA, in a retrospective analysis of 140,308 patients with type 2 diabetes.

Also with:
⬇️ 20% 🫀MACE
⬇️ 42% ☠️all cause mortality
⬇️ 0.34% a1c
⬇️2.9kg body weight

We need full randomized clinical trials before we can make conclusions of clear superiority

https://t.co/lNVh6UmMFY